{"certainAgreement":{"otherDetails":"The agreed point of publication is 12-18 months after database lock at the earliest.\n\n* Bayer will have up to 30/45 days to review publications, and may request an additional publication delay of up to 60 days to allow for filing a Patent Application (if applicable).\n* No publication of single center data should be done prior of publication if multi -center data.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"Per final PFS data (N=769) study unblinded; placebo-randomized subjects switched to sorafenib \\~31May2005 (N=216) that diluted final OS, sorafenib treatment effect. Final ITT, N=903, reported safety data include additional data and cleaning."},"pointOfContact":{"email":"clinical-trials-contact@bayerhealthcare.com","organization":"BAYER","title":"Therapeutic Area Head"}}